Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 - PubMed (original) (raw)

Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019

Junli Fan et al. Metabolism. 2020 Jun.

Abstract

Background: The pandemic of coronavirus disease 2019 (COVID-19) has become a global threat to public health. The lipid pathophysiology in COVID-19 is unknown.

Methods: In this retrospective longitudinal study, we monitored the serum lipids in 17 surviving and 4 non-surviving COVID-19 cases prior to their viral infections and duration the entire disease courses.

Results: In surviving cases, the low-density lipoprotein (LDL) levels decreased significantly on admission as compared with the levels before infection; the LDL levels remained constantly low during the disease progression and resumed to the original levels when patients recovered (pre-infection: 3.5 (3.0-4.4); on admission: 2.8 (2.3-3.1), p < 0.01; progression: 2.5 (2.3-3.0); discharge: 3.6 (2.7-4.1); median (IQR), in mmol/L). In non-surviving patients, LDL levels showed an irreversible and continuous decrease until death (1.1 (0.9-1.2), p = 0.02 versus the levels on admission). The ratio changes of LDL levels inversely correlated with ratio changes of high-sensitivity C-reactive protein levels. Logistic regression analysis showed increasing odds of lowered LDL levels associated with disease progression (odds ratio: 4.48, 95% IC: 1.55-12.92, p = 0.006) and in-hospital death (odds ratio: 21.72, 95% IC: 1.40-337.54, p = 0.028).

Conclusions: LDL levels inversely correlated to disease severities, which could be a predictor for disease progress and poor prognosis.

Keywords: COVID-19; LDL; Lipid; Odds ratio.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors do not have any professional and financial affiliations that may be perceived to have biased the presentation.

Figures

Fig. 1

Ratio changes for LDL (A), HDL (B) and TC (C) in COVID-19 patients during the course of disease. For each data point, the ratio is normalized to the levels of LDL, HDL and TC prior to infection for the same patient. The days listed are the duration (median (IQR)) for each period during the disease course. The date on admission is set as “day 0”. Data is presented as “mean ± 95% confidence interval”. # indicates p < 0.05 as compared to the levels of pre-infection stage, and * indicates p < 0.05 as compared to the levels on admission, by a Mann-Whitney U test. The sample actual values at each stage are listed in Supplementary Table S1. The ratios of hsCRP at each time point are normalized to the levels prior to infection in the same patients. Pearson correlation coefficient analysis show the ratios of hsCRP significantly inversely correlated with the ratios of LDL (D), HDL (E) and TC (F) during the disease course; n = 33 data pairs for each analysis.

Cited by

COVID-19 and ethnicity: A novel pathophysiological role for inflammation.
Vepa A, Bae JP, Ahmed F, Pareek M, Khunti K. Vepa A, et al. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1043-1051. doi: 10.1016/j.dsx.2020.06.056. Epub 2020 Jun 30. Diabetes Metab Syndr. 2020. PMID: 32640416 Free PMC article. Review.
High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratification.
Dugail I, Amri EZ, Vitale N. Dugail I, et al. Biochimie. 2020 Dec;179:257-265. doi: 10.1016/j.biochi.2020.07.001. Epub 2020 Jul 8. Biochimie. 2020. PMID: 32649962 Free PMC article.
Fraction of plasma exomeres and low-density lipoprotein cholesterol as a predictor of fatal outcome of COVID-19.
Usenko T, Miroshnikova V, Bezrukova A, Basharova K, Landa S, Korobova Z, Liubimova N, Vlasov I, Nikolaev M, Izyumchenko A, Gavrilova E, Shlyk I, Chernitskaya E, Kovalchuk Y, Slominsky P, Totolian A, Polushin Y, Pchelina S. Usenko T, et al. PLoS One. 2023 Feb 9;18(2):e0278083. doi: 10.1371/journal.pone.0278083. eCollection 2023. PLoS One. 2023. PMID: 36758022 Free PMC article.
Molecular Mechanisms Responsible for Diabetogenic Effects of COVID-19 Infection-Induction of Autoimmune Dysregulation and Metabolic Disturbances.
Grubišić B, Švitek L, Ormanac K, Sabo D, Mihaljević I, Bilić-Ćurčić I, Omanović Kolarić T. Grubišić B, et al. Int J Mol Sci. 2023 Jul 18;24(14):11576. doi: 10.3390/ijms241411576. Int J Mol Sci. 2023. PMID: 37511334 Free PMC article. Review.
Finding answers in lipid profile in COVID-19 patients.
Sampedro-Nuñez M, Aguirre-Moreno N, García-Fraile Fraile L, Jiménez-Blanco S, Knott-Torcal C, Sanz-Martin P, Fernández-Jiménez G, Marazuela M. Sampedro-Nuñez M, et al. Endocrine. 2021 Dec;74(3):443-454. doi: 10.1007/s12020-021-02881-0. Epub 2021 Oct 19. Endocrine. 2021. PMID: 34668172 Free PMC article.

References

1. Xu X., Chen P., Wang J. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457–460. doi: 10.1007/s11427-020-1637-5. - DOI - PMC - PubMed
1. Lu R., Zhao X., Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. S0140-6736(20)30251-8. - PMC - PubMed
1. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-NCOV and naming it SARS-COV-2. Nat Microbiol. 2020 doi: 10.1038/s41564-020-0695-z. - DOI - PMC - PubMed
1. Zhou P., Yang X.L., Wang X.G. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 doi: 10.1038/s41586-020-2012-7. - DOI - PMC - PubMed
1. Wan Y., Shang J., Graham R. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020 doi: 10.1128/JVI.00127-20. - DOI - PMC - PubMed

Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 - PubMed (original) (raw)